Parkman Healthcare Partners LLC Has $6.02 Million Stock Position in CVRx, Inc. (NASDAQ:CVRX)

Parkman Healthcare Partners LLC boosted its stake in CVRx, Inc. (NASDAQ:CVRX - Free Report) by 52.6% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 682,897 shares of the company's stock after buying an additional 235,277 shares during the period. Parkman Healthcare Partners LLC owned approximately 2.81% of CVRx worth $6,016,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of CVRX. Centiva Capital LP acquired a new position in shares of CVRx in the third quarter valued at approximately $178,000. PDT Partners LLC acquired a new position in shares of CVRx in the third quarter valued at about $543,000. International Assets Investment Management LLC acquired a new position in shares of CVRx in the third quarter valued at about $338,000. SG Americas Securities LLC acquired a new position in shares of CVRx in the third quarter valued at about $108,000. Finally, Squarepoint Ops LLC grew its position in shares of CVRx by 26.3% during the 2nd quarter. Squarepoint Ops LLC now owns 91,999 shares of the company's stock worth $1,103,000 after purchasing an additional 19,165 shares in the last quarter. Institutional investors and hedge funds own 75.27% of the company's stock.

CVRx Trading Down 1.6 %

NASDAQ CVRX traded down $0.24 on Wednesday, hitting $14.79. The company's stock had a trading volume of 135,901 shares, compared to its average volume of 275,035. The firm has a market cap of $358.81 million, a PE ratio of -5.55 and a beta of 1.20. The company's 50-day moving average is $11.82 and its 200 day moving average is $10.12. The company has a quick ratio of 10.23, a current ratio of 11.32 and a debt-to-equity ratio of 0.76. CVRx, Inc. has a 1-year low of $6.40 and a 1-year high of $33.13.

CVRx (NASDAQ:CVRX - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.12). The business had revenue of $13.37 million for the quarter, compared to analyst estimates of $13.28 million. CVRx had a negative return on equity of 89.06% and a negative net margin of 123.75%. During the same quarter last year, the firm posted ($0.43) EPS. As a group, analysts predict that CVRx, Inc. will post -2.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on CVRX shares. Lake Street Capital increased their target price on shares of CVRx from $12.00 to $15.00 and gave the stock a "buy" rating in a research report on Wednesday, October 30th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $14.00 target price on shares of CVRx in a report on Wednesday, October 23rd. Canaccord Genuity Group raised their price objective on CVRx from $15.00 to $17.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. Craig Hallum raised their price target on shares of CVRx from $15.00 to $20.00 and gave the company a "buy" rating in a research note on Monday, November 4th. Finally, Piper Sandler restated an "overweight" rating and issued a $16.00 price target (up from $13.00) on shares of CVRx in a research note on Wednesday, October 30th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, CVRx currently has a consensus rating of "Moderate Buy" and a consensus price target of $15.83.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.